ARGX Earnings Prediction
The chart below shows how ARGX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ARGX sees a -1.30% change in stock price 10 days leading up to the earnings, and a +1.52% change 10 days following the report. On the earnings day itself, the stock moves by +1.17%. This data can give you a slight idea of what to expect for the next quarter's release.
ARGX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
573.24M
--
20.02%
Gross Margin
89.69%
--
0.74%
Operating Margin
2.82%
--
-130.65%
Net Margin
15.95%
--
161.90%
EPS
1.39
--
183.67%
No Data Available
ARGX Earnings Analysis
argenx SE American Depositary Shares Corporation (ARGX.O) Earnings Conference Call
Positive
Product Sales Surge: 1. Strong Product Sales Growth: Total product net sales reached $573 million in Q3 2024, reflecting a 20% quarter-over-quarter growth and a remarkable 74% increase compared to the same quarter last year.
CIDP Launch Success: 2. Successful CIDP Launch: The CIDP launch has successfully delivered treatment to over 300 patients in its first quarter, with revenue approaching that of the first quarter of the MG launch.
Consistent High Profitability: 3. High Gross Margin: The company maintained a gross margin of 90% in Q3 2024, consistent with previous quarters, indicating strong profitability from product sales.
Strong Cash Reserves: 4. Significant Cash Position: Argenx reported a cash balance of $3.4 billion at the end of Q3 2024, an increase of $272 million during the quarter, providing a solid foundation for future investments.
Clinical Effectiveness of VYVGART: 5. Positive Clinical Outcomes: Over 50% of gMG patients on VYVGART achieved meaningful treatment goals, with 25% tapering to 0 mg of steroids within 12 months, showcasing the drug's effectiveness.
Negative
Operating Expenses Increase: 1. Increased Operating Expenses: Total operating expenses in Q3 2024 reached $575 million, a $40 million increase compared to Q2 2024, driven by higher SG&A and R&D costs.
Operating Loss Analysis: 2. Year-to-Date Operating Loss: The year-to-date operating loss stands at $125 million, indicating ongoing financial challenges despite recent revenue growth.
Discontinuation of Development: 3. Discontinued Development in MN: The decision to discontinue the development of efgartigimod in membranous nephropathy was made due to insufficient efficacy signals from interim data, reflecting a setback in the pipeline.
Cash Guidance Withdrawal: 4. Cash Guidance Withdrawal: The company has withdrawn its cash guidance for 2024, indicating uncertainty in financial projections moving forward.
Gross-to-Net Ratio Analysis: 5. High Gross-to-Net Ratio: The gross-to-net ratio remains around 12%, suggesting limited pricing power and potential challenges in revenue realization despite strong sales.
ARGX FAQs
How does ARGX typically perform around its earnings report dates?
Is argenx SE (ARGX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ARGX Earning Call Sentiment
argenx SE (ARGX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
ARGX.O
-0.02%Positive
The earnings call summary indicates positive financial performance with 20% growth in net sales and a net profit. The strategic plan highlights pipeline expansion and market growth, particularly in CIDP and MG. The Q&A section reinforces these positives with smooth patient transitions and favorable payer policies. Despite some unclear responses, the overall sentiment is positive, with optimistic guidance and strategic plans likely to boost stock price.